- Poster presentation
- Open Access
Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials
© Klokker et al; licensee BioMed Central Ltd. 2015
- Published: 29 May 2015
- Knee Osteoarthritis
- Pain Outcome
- Selective Outcome
- International Initiative
- Outcome Instrument
The selection of appropriate outcomes is crucial when designing, and subsequently interpreting clinical trials, in order to directly compare the effects of different interventions in ways that minimize bias. The same is likely to apply for systematic reviews and meta-analyses. Although protocol registration for systematic reviews is still not mandatory, reviewers should be strongly encouraged to register the protocol, in order to identify - a priori - the proposed methodological approach, including all outcomes of interest. This will help to minimize the likelihood of biased post hoc decisions in review methods, such as selective outcome reporting.
A group of international experts convened to address issues regarding the need to develop hierarchical lists of outcome measurement instruments for a particular outcome for meta-analyses. Meta-analysis of knee osteoarthritis (OA) trials, and the assessment of pain as an outcome, was used as an exemplar to assess how ‘Outcome Measures in Rheumatology’ (OMERACT) and other international initiatives might contribute in this area. The meeting began with formal presentations of background topics, empirical evidence from the literature, and a brief introduction to two existing hierarchical lists of pain outcome measures recommended for meta-analyses of knee OA trials.
After discussions most participants agreed that there is a need to develop a methodology for generation of hierarchical lists of outcome instruments for use to guide meta-analyses. Tools that could be used to steer development of such a prioritized list are the COSMIN checklist and the OMERACT filter 2.0. For future research we suggest that among outcome instruments frequently reported in trials for the same domain, those with the best measurement properties (e.g., validity and reliability) would achieve high, if not the highest rankings for use on a hierarchical list.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.